Objectives: To determine long-term survival rates of patients who underwent lung volume reduction surgery (LVRS) for emphysema and the factors associated with longer survival, and to evaluate levels of perceived dyspnea and health-related quality of life (HRQL) after a follow-up period of 3 to 5.5 years. Design: Retrospective observational study. Setting: Academic medical center Methods: Telephone and postal surveys were used to obtain patient dyspnea scores and HRQL scores. Hospital databases and state registries were searched to determine patient survival and pulmonary function. 
L
ung volume reduction surgery (LVRS) was reintroduced as a means of improving outcomes for patients with severe COPD; however, little information is available regarding outcomes beyond the 3-year postoperative period. In one study 1 with follow-up of 26 LVRS patients at 4 years, benefits remained in only 20% of patients. Other reports 2, 3 suggest that although absolute benefits persist at 3 years relative to presurgical levels, there is a progressive decline in lung function parameters, exercise tolerance, and increasing oxygen dependence as the time from surgery lengthens. Compared to standard medical care, LVRS has been shown to offer a significant survival benefit after 24 months of follow-up (82% vs 64%). 4 Available shortterm data from randomized controlled trials indicate LVRS improves lung function, walk distance, and health-related quality of life (HRQL) compared to usual medical care, 5 and pulmonary rehabilitation. 6 Few studies of LVRS have considered HRQL, 6 -8 particularly disease-specific quality of life. 9, 10 These end points are important because care in late-stage COPD can be considered as essentially palliative. We have previously reported 11 the short-term effectiveness of LVRS in a cohort of 54 patients, with a median follow-up of 788 days, and demonstrated significant improvements in lung function and 6-min walk distance, and an appreciable mortality rate of 14.8% at 90 days after surgery. These results were consistent with previous reports. [12] [13] [14] The aim of this study was to determine longerterm mortality data after LVRS, and to examine what factors are associated with longer survival. We also sought to determine what qualitative benefits are sustained after a follow-up period in the range of 3 to 5.5 years, in terms of perceived dyspnea and HRQL of patients and their caregivers.
Materials and Methods

Patient Selection
Fifty-four patients underwent LVRS at The Queen Elizabeth Hospital in Adelaide, South Australia, between 1996 and 1997. 11 Of 30 surviving patients, 29 patients were available for follow-up in this study. One patient could not be contacted, and this patient's survival status was confirmed by a search of the state death registry. The criteria 11 for LVRS eligibility satisfied by all LRVS recipients in this study are listed in Table 1 .
Operative Technique
All subjects underwent bilateral, stapled, videoscopic resections (upper lobe, n ϭ 42; mixed, n ϭ 2; or lower lobe, n ϭ 11) without buttressing (except for unilateral buttressing in several latter patients as part of an intrapatient comparison trial) according to the pattern of emphysema determined by perfusion and CT scanning.
Study Design
This study was conducted using a telephone survey. Survival status was ascertained by searching the institutional patient record database and the state death registry. Letters explaining the purpose of the study were mailed to all subjects, inviting their participation. All patients were telephoned over a 3-week period to obtain informed consent, and dyspnea was graded at that time. HRQL questionnaires were mailed out for self-administration by patients and their caregivers, where present.
Dyspnea
Dyspnea was graded using two scales. Firstly, the modified Medical Research Council (MRC) dyspnea scale was used. This is scored on a 5-point scale from 0 to 4, where grade 0 describes the subject as "not troubled by shortness of breath except with strenuous exercise," and grade 4 describes the subject as "too breathless to leave the house or breathless when dressing or undressing." 15 The second scale used was the Mahler baseline dyspnea index (BDI). The Mahler BDI is a multidimensional grading of dyspnea, using the categories of "functional impairment," "magnitude of task," and "magnitude of effort" on a scale of 0 to 4, where 4 represents best and 0 represents worst. 16 The BDI was used to determine current dyspnea (36 to 65 months after LVRS) in preference to the transition dyspnea index because there was a substantial risk of subject recall bias in evaluating change compared to shortly after the procedure. All assessments of patient dyspnea were conducted by the same person to eliminate interobserver error.
Post-LVRS HRQL
HRQL was assessed using the Dartmouth Primary Care Co-operative Quality of Life questionnaire (COOP), 17 modified for use in COPD, as previously reported. 18 The modifications . Secondly, in order to more appropriately relate to the level of activity of patients with severe COPD, the item regarding physical condition (What is the most strenuous level of activity you can do for 2 min?) was altered by deleting the "heavy" category (jog at fast pace) and adding an "extremely light" category (eating, getting out of bed). The remaining eight items refer to the emotional and overall condition and how these impact on the ability to perform daily and social activities, and the perception of pain and change in condition. The COOP questionnaire features a simple graphical layout, has documented reliability and validity in a range of settings including respiratory disease, 19, 20 and was selected in view of the level of morbidity of the subjects to be enrolled. High COOP scores indicate lower perceptions of HRQL.
Caregiver Burden
To determine the caregiver burden associated with caring for a patient who has undergone LVRS, the caregivers completed the Caregiver Burden Scale, which has proven validity and reliability in chronic illness. 21 
Pulmonary Function
Lung function data were obtained on survivors from The Queen Elizabeth Hospital's Pulmonary Function Laboratory database. Patient data were only included in the analysis if the follow-up time was Ͼ 2 years. The data of four subjects were excluded because the follow-up on lung function data was available for Ͻ 2 years.
Statistical Analysis
Data are provided as mean Ϯ SE. Differences between pre-LVRS and follow-up respiratory parameters and outcomes were analyzed using paired and unpaired t tests. Preoperative and postoperative dichotomous variables and outcomes that were used as predictors of mortality were analyzed for statistical significance using the Pearson 2 test. All p values were considered significant if Ͻ 0.05. Kaplan-Meier survival analysis was performed to determine survival probability, and Cox proportional hazards models were used to determine preoperative and postoperative factors influencing long-term survival. Institutional ethics committee approval was obtained for this study.
Results
Baseline characteristics of the 54 LVRS recipients are shown in Table 2 . As previously reported, 11 no deaths occurred in the first 2 postoperative weeks. Perioperative mortality was 5.5% (3 of 54 patients) at 30 days, 14.8% (8 of 54 patients) at 90 days, and 25.9% (14 of 54 patients) at the median follow-up time of 788 days. A homogeneous pattern on perfusion Q scan significantly correlated with mortality (p ϭ 0.007). The underlying pathology in those who died included ischemic heart disease (n ϭ 5), cardiac failure/arrhythmia (n ϭ 5), respiratory failure associated with sputum retention or failure to re-expand (n ϭ 6), and probable pneumonia (n ϭ 8). Of note, one patient died (electromechanical dissociation/ ARDS) and two patients required urgent treatment following tension pneumothorax occurring at least 4 days after removal of drains on that side. Another death was precipitated by major postoperative air leaks in the only patient in whom surgery was complicated by excessive pleural adhesions that proved to be densely adherent, on the basis of asbestos pleuritis.
An analysis of factors associated with mortality within 90 days of LVRS was conducted. Pre-LVRS exercise tolerance, as indicated by the mean 6-min walk distance, was significantly reduced in those dying within 90 days compared to those who survived: 217 Ϯ 51 m vs 323 Ϯ 18 m (p ϭ 0.046). Consistent with the underlying pathology in those who died, postoperative pneumonia was significantly associated with mortality (p ϭ 0.005). Postoperative length of stay (LOS) was significantly lengthened in those who died within 90 days of surgery compared to those who survived this time point: 36.1 Ϯ 5.2 days vs 18.8 Ϯ 3.0 days (p ϭ 0.02).
Twenty-nine of 30 surviving patients who underwent LVRS were available for follow-up with the survey. Median duration of survivor follow-up was 49 months (range, 36 to 66 months). Table 3 shows the mean modified MRC scale and Mahler BDI scores for all patients prior to LVRS and for the survivors at baseline and follow-up. There was a statistically significant reduction in dyspnea for survivors at follow-up compared to baseline (p Յ 0.01). Among survivors, 58% (15 of 26 patients) improved at least one level on the modified MRC scale, and 50% (11 of 22 patients) improved by more than one level in all three scales of the Mahler BDI, compared to their baseline values. When dyspnea benefits were considered as a proportion of all subjects undergoing LVRS and not just the survivor fraction, 27.8% and 20.4% of all subjects experienced ongoing reductions in dyspnea according to the MRC scale and Mahler BDI scores, respectively.
The preoperative and postoperative physical and respiratory variables of survivors compared to nonsurvivors are listed in Table 4 . Of the preoperative parameters, a higher mean body mass index (BMI) was associated with improved survival (p ϭ 0.002). We conducted a post hoc analysis of the relationship of BMI groupings to postoperative mortality and morbidity. Based on BMI, subjects were categorized into low (18 None of the preoperative respiratory parameters were significantly associated with increased longterm survival. Although diffusing capacity of the lung for carbon monoxide (Dlco) was higher in survivors, this did not reach significance at conventional levels (p ϭ 0.09). In terms of postoperative variables, only mean LOS was significantly associated with increased survival (p ϭ 0.015). No individual postoperative complication, such as lung collapse or pneumothorax, pneumonia, or atrial fibrillation, was associated with increased mortality. There was an observed trend toward a smaller absolute change in the 6-min walk distance (post-LVRS compared to pre-LVRS) being associated with increased mortality (p ϭ 0.095). The site of resection did not significantly influence survival. The survival rate in those who underwent lower resection was 73% (8 of 11 patients) compared to 51% (21 of 41 patients) with upper resection (p ϭ 0.20). Table 5 shows results for patient HRQL as measured by the COOP charts, and for caregiver burden, as measured using the Caregiver Burden Scale. Patient COOP scores and Caregiver Burden Scale (Fig 1) showed that after the initial 90-day mortality rate of 8 of 54 patients (14.8%), postoperative mortality at the mean follow-up time of 37 months was 33.3% (18 of 54 patients). At the maximum post-LVRS follow-up time of 65.5 months, the mortality rate was 44% (24 of 54 patients). The 2-year, 3-year, 4-year, and 5-year survival rates in our patient group were 74%, 67%, 63%, and 56%, respectively. Table 6 shows the change in lung function parameters of survivors. To determine whether data from patients with shorter follow-up (2 to 3 years) contributed significantly to and thus overestimated the observed significant lung function benefits observed at the mean follow-up time, a post hoc analysis was conducted for subjects with Ն 24 months and Ն 36 months of follow-up (Table 6 ). For all 26 subjects with at least 2 years of lung function data follow-up, all mean pulmonary function parameters (FEV 1 , FVC, total lung capacity [TLC] percentage of predicted, residual volume [RV] percentage of predicted and Dlco/alveolar volume [Va] percentage of predicted) were significantly improved compared to their best pre-LVRS values. There were 10 patients (38%) and 11 patients (42%) with sustained increases in FEV 1 Ͼ200 mL and FVC Ͼ 400 mL, respectively. For the 20 patients with at least 3 years of follow-up, all mean pulmonary function parameters except absolute FEV 1 and FVC were significantly improved compared to their best pre-LVRS values. Six patients (30%) and seven patients (35%) had sustained increases in FEV 1 Ͼ200 mL and FVC Ͼ 400 mL, respectively. When these benefits were considered as a proportion of all subjects undergoing LVRS, 11.1% and 13.0% of patients experienced ongoing benefits after 3 years in FEV 1 and FVC, respectively.
Supplemental oxygen use was also considered as a measure of functional impairment. Ten patients with a mean follow-up duration of 55 months required oxygen therapy (continuous, n ϭ 8; portable [for exertion only], n ϭ 2) compared to 14 patients who required oxygen therapy prior to surgery. Of these 10 patients, 6 patients did not require oxygen prior to LVRS. Of the 14 patients requiring oxygen prior to LVRS, 8 patients were deceased at follow-up and 2 patients had no requirement.
Discussion
We have reported data on 54 patients followed up for up to 5.5 years after LVRS. Among the survivors, LVRS has resulted in significant ongoing reductions in dyspnea. At least 50% of surviving patients experienced ongoing relief of dyspnea compared to presurgery levels on both dyspnea scales used. Of the 55% of patients surviving, all mean pulmonary function parameters were significantly improved at 2 years after surgery compared to their best pre-LVRS values. This continued beyond 3 years, except for absolute FEV 1 and FVC. Of the preoperative patient physical parameters, only a higher mean BMI was significantly associated with long-term survival. Severely impaired preoperative exercise tolerance, which was demonstrated to be significantly associated with 90-day mortality, did not influence longterm survival. Consistent with the majority of the LVRS literature, none of the preoperative respiratory parameters predicted long-term survival. Only one postoperative variable, mean LOS, was significantly associated with short-and long-term survival. Although, postoperative pneumonia was significantly associated with 90-day mortality, no individual postoperative complications were found to be significantly associated with mortality in the long term.
Given the limitations inherent in a retrospective analysis of a case series and absence of adequate presurgical HRQL measures for follow-up analysis, we have demonstrated reductions in dyspnea comparable to previous reports. Gelb et al 22 reported a reduction in dyspnea grade Ն 1 at 3-year, 4-year, and 5-year follow-up in 46%, 27%, and 15% of subjects, respectively. Approximately 30% of our patients who had dyspnea relief did not have an increase of Ͼ 200 mL of FEV 1 after surgery. Post-LVRS improvements in dyspnea have been related to increased lung elastic recoil, 23, 24 reduced hyperinflation, 24 improved respiratory muscle function, 24 and reduced mechanical restraints on tidal volume, 25 all of which may be independent of FEV 1 . 26 Our results show that a lower BMI has an adverse impact on longer-term survival after LVRS. This was not due to any effect of patients with very poor nutritional status, as patients with a BMI Ͻ 18 were not eligible for surgery. In particular, a post hoc analysis indicated that a BMI of between 25 and 30 was significantly associated with improved survival. We also observed a trend for a low BMI (18 to Ͻ20) to be associated with a prolonged after surgery LOS. Nutritional status, specifically depletion, has been linked to morbidity 27 and mortality 28 in patients with COPD, and with adverse LVRS outcomes in the early postsurgical period. 29, 30 A study 30 with 6-month follow-up of 23 patients has demonstrated significantly higher mean BMI and fat-free mass index in patients without major complications. The significantly increased mortality among those with both low and normal BMI, compared with those with BMI Ն 25 to 30, may be related to masking of fat-free muscle depletion in the apparently normal weight patients 31, 32 as a contributing factor. This may need to be considered when planning and selecting candidates for LVRS.
We were unable to confirm the high-risk baseline factors for mortality of FEV 1 Յ 20% predicted and Dlco Յ 20% predicted or a homogeneous pattern of emphysema recently reported on preliminary data by the National Emphysema Treatment Trial (NETT) Research Group. 33 We did detect a trend toward a higher Dlco predicting survival. However, only 5 of 54 patients in our uncontrolled case series had an FEV 1 Յ 20% at baseline, and only one subject had a Dlco at baseline of Յ 20%. The NETT investigators also reported a much higher 30-day mortality rate than our study (16% vs 5.5%). It is of note that with less severely affected patients than in the NETT, we were able to demonstrate substantial ongoing functional benefits from LVRS.
There is clear variation in function and quality of life in our patient group. Mean COOP scores 3 to 5.5 years after LVRS were better than those reported in a trial of hospital at home care vs standard hospital care for patients with COPD 34 and in a group of elderly patients in residential care, 35 even though an extra item pertaining to breathing was included in our "modified" COOP questionnaire. A significant limitation of this study is that we have inadequate pre-LVRS COOP data and follow-up lung function data to make statistically valid pre-LVRS and post-LVRS comparisons for these variables. Few studies have reported HRQL outcomes after LVRS. A study by Leyenson et al 36 showed short-term improvements in HRQL were not correlated with routine measures of pulmonary function, gas exchange, and exercise tolerance. Another study 37 showed that improvements in Medical Outcomes Study Short Form-36 scores at 6 months were significantly associated with improvements in FEV 1 . An increased level of performance of daily activities may maintain exercise tolerance and prevent physical deconditioning in the presence of gradually declining objective lung function benefits. There was no significant correlation between overall patient HRQL and caregiver burden, nor was there a significant independent relationship between care burden scores and the COOP social support item. Caregiver burden was lower for our patients' caregivers than that reported by those caring for people with rheumatoid arthritis 38 and for people 3 years after stroke. 21 Although interpretation of this data is limited by the lack of preoperative comparison data, it suggests that LVRS is unlikely to impose a significant extra burden on most caregivers.
The number of subjects with sustained increases in lung function at follow-up compared to pre-LVRS is consistent with that previously reported. Gelb et al 1, 39 demonstrated that increases in FEV 1 Ͼ 200 mL and/or FVC Ͼ 400 mL occurred in 46% of patients at 2 years and in 35% of subjects at 3 years, and Flaherty et al 2 reported FEV 1 improvements Ͼ 200 mL in 29% of patients at 3 years.
Post-LVRS survival rates vary across studies. Our follow-up has shown a survival rate of 67% at 3 years after LVRS, 63% at 4 years, and 56% at 5 years. This compares favorably with reported 3-year, 4-year, and 5-year survival rates of 69%, 54%, and 42%, respectively, by Gelb et al. 26 In contrast, our survival rates compare unfavorably with other reports of 5-year survival of 74% 3 and the 3-year survival of 82%. 2 These differences may be explained by the younger age, 2,3 less dyspnea, 2 and better exercise tolerance 3 at baseline in these study subjects, compared to our study subjects.
It is arguable, however, that analysis of outcomes in the survivor fraction exaggerates the true benefits of LVRS. When lung function and dyspnea benefits were considered as a proportion of all of those subjects who underwent the procedure, the benefits were reduced and, at best, would seem marginal. Significant increases in FEV 1 and FVC after 3 years were demonstrable in 11% and 13% of all subjects, respectively. Similarly, 28% and 20% of all subjects experienced ongoing dyspnea relief as measured with the MRC scale and Mahler BDI. However, in a discussion of survival benefits associated with LVRS, it is necessary to consider the prognosis for people with COPD who receive optimal medical management only. Varying survival rates are reported in the literature. In the study by Almagro et al 40 in 135 elderly patients (mean age, 72.2 Ϯ 9.3 years) who were hospitalized for acute exacerbations of COPD, the survival rate was 64% at 2 years. Given that people undergoing LVRS are a highly selected group of patients who usually undergo presurgical and postsurgical respiratory rehabilitation programs that in themselves are known to be beneficial, 41 a direct comparison of our 3-year to 5-year survival rates and associated benefits in outcome measures with those reported in the literature for medical management alone possibly is not valid. Meyers et al 4 compared 3-year survival rates for patients who were eligible for but were denied LVRS and proceeded to receive medical care, and those that underwent LVRS. They reported 3-year survival rates of 64% in the medical group, and 82% for the LVRS group, suggesting that the survival benefit conferred by LVRS is indeed meaningful. Indirect measures, such as rates of hospital admissions for exacerbations of COPD, in addition to the direct benefits of LVRS should be considered in future studies because these also have significant impacts on patients and health-care systems.
In summary, we have demonstrated sustained improvements in perceived dyspnea and lung function from LVRS that are preserved beyond 3 years. These improvements appear to be ongoing among those with up to 5.5-year survival. The HRQL of survivors is comparable to that experienced by the "healthy" elderly in the community. LVRS does not appear to impose an onerous burden on patient caregivers. Importantly, we have identified BMI as a predictor of longer postsurgical survival. This may have implications for selection of LVRS candidates and for preoperative management.
